- Email: [email protected]
Does re-resection of liver metastases for breast cancer hepatic metastases improve survival?
Electronic Poster Abstracts Results: Nineteen patients were found to be eligible for the study. Six patients were submitted to surgery for uterine cancer liver metastases while the other 13 patients were submitted to liver resection for cervical cancer liver metastases. One patient with uterine cancer and two patients with cervical cancer were diagnosed with synchronous hepatic metastases while in the other 16 cases metachronous lesions were diagnosed. Early postoperative death encountered in a single patient with metachronous liver metastases and pelvic recurrence after surgically treated cervical cancer and was not related to liver surgery. The median overall survival after liver resection for patients with cervical cancer liver metastases was 17,9 months, slightly improved for cases with metachronous lesions (p = 0,587) while the median overall survival after liver resection for uterine cancer liver metastases was 22 months. Conclusions: Liver resections can be safely performed for hepatic metastases originating from uterine body and cervix primaries.
EP01A-071 DOES RE-RESECTION OF LIVER METASTASES FOR BREAST CANCER HEPATIC METASTASES IMPROVE SURVIVAL? N. Bacalbasa1, I. Balescu2, S. Dima3, V. Brasoveanu3 and I. Popescu3 1 Carol Davila University of Medicine and Pharmacy, 2 Ponderas Hospital, and 3Fundeni Clinical Institute, Gastroenterology and Hepatic Transplantation Center, Romania Aim: To demonstrate the safety and benefits in terms of survival of liver resections for hepatic recurrences originating from breast cancer Material and method: Between 2002e2015 in “Dan Setlacec” Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute ten patients were submitted to iterative liver resections for isolated breast cancer liver metastases. Results: The mean interval between surgery for breast cancer and second surgery for liver metastases was 58 months while the median survival after performing liver reresection for recurrent breast cancer liver metastases was 24 months (range 8e44 months). The early postoperative mortality rate was null. Six patients are still alive at the time of ending the study, with no sign of recurrent disease. Conclusions: Re-resection for isolated liver metastases from breast cancer can be safely performed and may significantly improve survival.
EP01A-072 HEPATIC RESECTION FOR PARENCHIMATOUS LESIONS AS PART OF PRIMARY CYTOREDUCTION FOR ADVANCED STAGE EPITHELIAL OVARIAN CANCER N. Bacalbasa1, I. Balescu2, S. Dima3, V. Brasoveanu4 and I. Popescu4 1 Carol Davila University of Medicine and Pharmacy, 2 Ponderas Hospital, 3Fundeni Clinical Insitute, and HPB 2016, 18 (S1), e1ee384
e187
4
Fundeni Clinical Institute, Gastroenterology and Hepatic Transplantation Center, Romania Aims: To evaluate the role of surgical resection for parenchimatous liver metastases from ovarian cancer at the moment of primary cytoreduction. Method: At the moment of primary cytoreduction, seven patients with ovarian cancer liver metastases were submitted to hepatic resections in Fundeni Clinical Hospital between January 2002 e April 2014. Liver metastases entirely surrounded by normal liver parenchyma were classified as hematogenous lesions. Results: The mean age at the moment of primary cytoreduction was 58 years. Two of the seven patients were submitted to neo-adjuvant chemotherapy. The main histopathological types were serous (5 cases), endometrial (1 case) and other subtypes (1 case). In six cases an R0 resection was performed. Minor hepatectomies (involving less than 2 liver segments) were performed in five cases, major hepatectomy (resection of more than 2 liver segments) was performed in one case while in another cases radiofrequncy ablation was performed. Postoperative morbidity was 14% (1/7 cases) while postoperative mortality was 0. Long term outcomes revealed a 12 months median overall survival for cases with hematogenous liver metastases. Although patients submitted to liver resection for peritoneal seeding reported a better outcome (with a reported median survival of 108 months), this fact did not reach statistical significance. Conclusions: Hepatic resection for parenchimatous ovarian cancer liver metastases can be safely introduced as part of cytoreductive surgery and may improve survival.
EP01A-073 THE PROGNOSTIC VALUE OF IMMUNE PROFILE IN PRIMARY AND METASTASTIC COLORECTAL CANCER e THE OSLO-COMET STUDY V. J. Dagenborg1,2,3, S. Yaqub2, Å. A. Fretland2,4, O. Østrup5, V. Nygaard1, L. Silwal-Pandit6, G. M. Mælandsmo1, A. -L. Børresen-Dale6,7, A. H. Ree8,9, B. Edwin2,4,9 and K. Flatmark1,3,9 1 Department of Tumor Biology, Oslo University Hospital e Institute for Cancer Research, 2Department of HepatoPancreato-Biliary Surgery, Oslo University Hospital e Rikshospitalet, 3Department of Gastroenterological Surgery, Oslo University Hospital e The Norwegian Radium Hospital, 4Department of Clinical Research, Oslo University Hospital e The Intervention Centre, Norway, 5 Center of Genomic Medicine, Rigshospitalet, Denmark, 6 Department of Genetics, Oslo University Hospital e Institute for Cancer Research, 7KG Jebsen Center for Breast Cancer Research, Oslo University Hospital e Institute for Cancer Research, 8Department of Oncology, Akershus University Hospital, and 9University of Oslo e Institute of Clinical Medicine, Norway Introduction: The presence of tumor infiltrating lymphocytes (TILs) has been shown to influence the prognosis of primary colorectal cancer (CRC) and colorectal liver metastases (CLM), independent of the TNM classification. Studies show that regulatory T cells inhibit anti-tumor immune responses in CRC. Thus the composition of TILs may orchestrate the fate of tumors.
EP01A-071 DOES RE-RESECTION OF LIVER METASTASES FOR BREAST CANCER HEPATIC METASTASES IMPROVE SURVIVAL? N. Bacalbasa1, I. Balescu2, S. Dima3, V. Brasoveanu3 and I. Popescu3 1 Carol Davila University of Medicine and Pharmacy, 2 Ponderas Hospital, and 3Fundeni Clinical Institute, Gastroenterology and Hepatic Transplantation Center, Romania Aim: To demonstrate the safety and benefits in terms of survival of liver resections for hepatic recurrences originating from breast cancer Material and method: Between 2002e2015 in “Dan Setlacec” Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute ten patients were submitted to iterative liver resections for isolated breast cancer liver metastases. Results: The mean interval between surgery for breast cancer and second surgery for liver metastases was 58 months while the median survival after performing liver reresection for recurrent breast cancer liver metastases was 24 months (range 8e44 months). The early postoperative mortality rate was null. Six patients are still alive at the time of ending the study, with no sign of recurrent disease. Conclusions: Re-resection for isolated liver metastases from breast cancer can be safely performed and may significantly improve survival.
EP01A-072 HEPATIC RESECTION FOR PARENCHIMATOUS LESIONS AS PART OF PRIMARY CYTOREDUCTION FOR ADVANCED STAGE EPITHELIAL OVARIAN CANCER N. Bacalbasa1, I. Balescu2, S. Dima3, V. Brasoveanu4 and I. Popescu4 1 Carol Davila University of Medicine and Pharmacy, 2 Ponderas Hospital, 3Fundeni Clinical Insitute, and HPB 2016, 18 (S1), e1ee384
e187
4
Fundeni Clinical Institute, Gastroenterology and Hepatic Transplantation Center, Romania Aims: To evaluate the role of surgical resection for parenchimatous liver metastases from ovarian cancer at the moment of primary cytoreduction. Method: At the moment of primary cytoreduction, seven patients with ovarian cancer liver metastases were submitted to hepatic resections in Fundeni Clinical Hospital between January 2002 e April 2014. Liver metastases entirely surrounded by normal liver parenchyma were classified as hematogenous lesions. Results: The mean age at the moment of primary cytoreduction was 58 years. Two of the seven patients were submitted to neo-adjuvant chemotherapy. The main histopathological types were serous (5 cases), endometrial (1 case) and other subtypes (1 case). In six cases an R0 resection was performed. Minor hepatectomies (involving less than 2 liver segments) were performed in five cases, major hepatectomy (resection of more than 2 liver segments) was performed in one case while in another cases radiofrequncy ablation was performed. Postoperative morbidity was 14% (1/7 cases) while postoperative mortality was 0. Long term outcomes revealed a 12 months median overall survival for cases with hematogenous liver metastases. Although patients submitted to liver resection for peritoneal seeding reported a better outcome (with a reported median survival of 108 months), this fact did not reach statistical significance. Conclusions: Hepatic resection for parenchimatous ovarian cancer liver metastases can be safely introduced as part of cytoreductive surgery and may improve survival.
EP01A-073 THE PROGNOSTIC VALUE OF IMMUNE PROFILE IN PRIMARY AND METASTASTIC COLORECTAL CANCER e THE OSLO-COMET STUDY V. J. Dagenborg1,2,3, S. Yaqub2, Å. A. Fretland2,4, O. Østrup5, V. Nygaard1, L. Silwal-Pandit6, G. M. Mælandsmo1, A. -L. Børresen-Dale6,7, A. H. Ree8,9, B. Edwin2,4,9 and K. Flatmark1,3,9 1 Department of Tumor Biology, Oslo University Hospital e Institute for Cancer Research, 2Department of HepatoPancreato-Biliary Surgery, Oslo University Hospital e Rikshospitalet, 3Department of Gastroenterological Surgery, Oslo University Hospital e The Norwegian Radium Hospital, 4Department of Clinical Research, Oslo University Hospital e The Intervention Centre, Norway, 5 Center of Genomic Medicine, Rigshospitalet, Denmark, 6 Department of Genetics, Oslo University Hospital e Institute for Cancer Research, 7KG Jebsen Center for Breast Cancer Research, Oslo University Hospital e Institute for Cancer Research, 8Department of Oncology, Akershus University Hospital, and 9University of Oslo e Institute of Clinical Medicine, Norway Introduction: The presence of tumor infiltrating lymphocytes (TILs) has been shown to influence the prognosis of primary colorectal cancer (CRC) and colorectal liver metastases (CLM), independent of the TNM classification. Studies show that regulatory T cells inhibit anti-tumor immune responses in CRC. Thus the composition of TILs may orchestrate the fate of tumors.